-
3 weeks ago | 
nature.com | Naseema Gangat |Ayalew Tefferi
Venotoclax schedule in acute myeloid leukemia Acute myeloid leukemia (AML) afflicts older individuals (median age 68 years), the majority of whom are unfit to receive intensive induction chemotherapy.
-
1 month ago | 
onlinelibrary.wiley.com | Carlo Brugnara |Alessandro Vannucchi |Ayalew Tefferi
• , “ As I Recall the Beginning of the American Journal of Hematology Forty Years Ago ,” American Journal of Hematology ( ): , https://doi.org/10.1002/ajh.24205. • , “ The American Journal of Hematology in 2007 ,” American Journal of Hematology , no. ( ): – , https://doi.org/10.1002/ajh.21160. • and , “ The American Journal of Hematology, 2011 and Beyond ,” American Journal of Hematology , no. ( ): 1, https://doi.org/10.1002/ajh.21951.
-
1 month ago | 
onlinelibrary.wiley.com | Naseema Gangat |Ayalew Tefferi
Conflicts of Interest N.G. has served on the Advisory Board for DISC Medicine and Agios. References 1, , , et al., “Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients,” Mayo Clinic Proceedings 90, no. 12 (2015): 1623–1638, https://doi.org/10.1016/j.mayocp.2015.08.022. 2, , , et al., “One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience,” Mayo Clinic Proceedings 87, no. 1 (2012): 25–33.
-
1 month ago | 
nature.com | Daniel A. Arber |Ayalew Tefferi |Alessandro Vannucchi |Tiziano Barbui
AbstractA lively discussion persists regarding the diagnostic criteria for essential thrombocythemia (ET), primary myelofibrosis (PMF) and polycythemia vera (PV), particularly in relation to early/pre-fibrotic myelofibrosis (pre-PMF), a disease entity initially introduced in 2001 by the 3rd edition of the World Health Organization (WHO) classification. The definition and criteria used to diagnose pre-PMF have been progressively modified over time.
-
2 months ago | 
onlinelibrary.wiley.com | Ayalew Tefferi |Naseema Gangat
Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.
-
Dec 27, 2024 | 
onlinelibrary.wiley.com | Patricia Carey |Animesh Pardanani |Patrick Starlinger |Ayalew Tefferi
To the Editor, The management of symptomatic splenomegaly in myelofibrosis (MF) was revolutionized by the discovery of the JAK2V617F mutation and subsequent development of JAK2 inhibitors (JAKi) [1-4]. Currently, four JAKi are approved by the Food and Drug Administration (FDA) for treatment of MF: ruxolitinib, fedratinib, pacritinib, and momelotinib which alleviate symptomatic splenomegaly and constitutional symptoms. In the COMFORT I (ruxolitinib vs.
-
Dec 13, 2024 | 
onlinelibrary.wiley.com | Ayalew Tefferi |Vincent Ho
• , , , et al., “ Indication and Management of Allogeneic Haematopoietic Stem-Cell Transplantation in Myelofibrosis: Updated Recommendations by the EBMT/ELN International Working Group ,” Lancet Haematology ( ): – . • and , “ 2024 Update on Allogeneic Hematopoietic Stem Cell Transplant for Myelofibrosis: A Review of Current Data and Applications on Risk Stratification and Management ,” American Journal of Hematology ( ): – .
-
Oct 24, 2024 | 
nature.com | Tiziano Barbui |Alessandra Carobbio |Valerio De Stefano |Alessandro Rambaldi |Ayalew Tefferi
AbstractThis viewpoint summarizes findings from analyses of large personal patient databases of myeloproliferative neoplasms (MPNs) to assess the impact of thrombosis on mortality, disease progression, and second cancers (SC). Despite advances, the current incidence of arterial and venous thrombosis remains a challenge.
-
Jun 6, 2024 | 
onlinelibrary.wiley.com | Naseema Gangat |Ayalew Tefferi
DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request.
-
May 21, 2024 | 
onlinelibrary.wiley.com | Ayalew Tefferi |Animesh Pardanani |Naseema Gangat
EDITORIAL Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean? Ayalew Tefferi, Corresponding Author Ayalew Tefferi Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA Correspondence Ayalew Tefferi, Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
